Search research articles
Contact Us
Filters
Showing results (711-720 of 829) with videos related to
Page
of 83
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study
Richard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Carcinogenesis
|
May 28, 2015
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome
Lawson Eng, Abul Kalam Azad, Xin Qiu, et al.
The Journal of Clinical Investigation
|
October 7, 2021
Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models
Sita Awasthi, James J Knox, Angela Desmond, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 19, 2013
Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists
Ivar M McDonald, Robert A Mate, F Christopher Zusi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D Y C Heng, T K Choueiri, B I Rini, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
European Urology
|
August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
Rana R McKay, Nils Kroeger, Wanling Xie, et al.
European Urology
|
March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy
Arnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2004
Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides
Yong-Jin Wu, Li-Qiang Sun, Huan He, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Page
of 83
Search research articles
Search
Showing results (711-720 of 829) with videos related to
Sort By:
Page
of 83
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study
Richard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Carcinogenesis
|
May 28, 2015
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome
Lawson Eng, Abul Kalam Azad, Xin Qiu, et al.
The Journal of Clinical Investigation
|
October 7, 2021
Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models
Sita Awasthi, James J Knox, Angela Desmond, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 19, 2013
Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists
Ivar M McDonald, Robert A Mate, F Christopher Zusi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D Y C Heng, T K Choueiri, B I Rini, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
European Urology
|
August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
Rana R McKay, Nils Kroeger, Wanling Xie, et al.
European Urology
|
March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy
Arnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2004
Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides
Yong-Jin Wu, Li-Qiang Sun, Huan He, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Page
of 83